Evidence map›Paper›PMID 23100627›Full record

ArticleScience translational medicine2012

NADPH oxidase inhibits the pathogenesis of systemic lupus erythematosus.

Allison M Campbell, Michael Kashgarian, Mark J Shlomchik

Open access · greenAbstract read
In one paragraph

Article in Science translational medicine, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 145 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
145citing papers in PubMed, 2 pooled it
7.3field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

145 citing papers in PubMed, 2 syntheses or guidelines pooled it, 231 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Review
  5. Article
  6. Review
  7. Article
  8. Review
  9. Article
  10. The Role of NADPH Oxidase 2 in Leukocytes.Antioxidants (Basel, Switzerland) · 2025
    Review
  11. Sepsis-induced NET formation requires MYD88 but is independent of GSDMD and PAD4.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2025
    Article
  12. Review
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article

85 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Allison M CampbellDepartment of Immunobiology, Yale University School of Medicine, New Haven, CT 06511, USA.
Michael Kashgarian
Mark J Shlomchik
Yale University · US

Funding

MEDICAL SCIENTIST TRAINING PROGRAMT32GM007205 · NIGMS · YALE UNIVERSITY · PI KAZMIERCZAK, BARBARA I · 1985 to 2019
$42.9M
Toll-Like Receptors in Systemic Autoimmune DiseaseP01AR050256 · NIAMS · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI VIGLIANTI, GREGORY A. · 2004 to 2013
$13.4M
Mechanisms of Autoimmune Activation and Regulation by Innate Immune ReceptorsR01AI084958 · NIAID · YALE UNIVERSITY · PI SHLOMCHIK, MARK J · 2010 to 2014
$702k
The role of neutrophil extracellular traps and NADPH oxidase in SLE pathogenesisF30DK091993 · NIDDK · YALE UNIVERSITY · PI CAMPBELL, ALLISON MARIE · 2011 to 2012
$94k
NIAID NIH HHS R01 AI084958NIAID NIH HHS R01-AI084958NIAMS NIH HHS P01 AR050256NIAMS NIH HHS P01-AR050256NIDDK NIH HHS F30 DK091993NIDDK NIH HHS F30 DK091993-02NIGMS NIH HHS 2T32GM07205NIGMS NIH HHS T32 GM007205
6 · The paper itself

Abstract

Systemic lupus erythematosus (SLE) is an autoimmune disease characterized by loss of tolerance to self nucleic acids. The source of autoantigen that drives disease onset and progression is unclear. A candidate source of autoantigen is the neutrophil extracellular trap (NET), which releases nucleic acids into the extracellular environment, generating a structure composed of DNA coated with antimicrobial proteins. On the basis of in vitro and patient correlative studies, several groups have suggested that NETs may provide lupus autoantigens. The observation that NET release (NETosis) relies on activity of the phagocyte NADPH (reduced form of nicotinamide adenine dinucleotide phosphate) oxidase (Nox2) in neutrophils of both humans and mice provided a genetic strategy to test this hypothesis in vivo. Therefore, we crossed an X-linked nox2 null allele onto the lupus-prone MRL.Fas(lpr) genetic background and assessed immune activation, autoantibody generation, and SLE pathology. Counter to the prevailing hypothesis, Nox2-deficient lupus-prone mice had markedly exacerbated lupus, including increased spleen weight, increased renal disease, and elevated and altered autoantibody profiles. Moreover, heterozygous female mice, which have Nox2 deficiency in 50% of neutrophils, also had exacerbated lupus and altered autoantibody patterns, suggesting that failure to undergo normal Nox2-dependent cell death may result in release of immunogenic self-constituents that stimulate lupus. Our results indicate that NETosis does not contribute to SLE in vivo; instead, Nox2 acts to inhibit disease pathogenesis, making this enzyme an important target for further study and a candidate for therapeutic intervention.

Indexed as

AnimalsAntibody FormationCell ProliferationDNAExtracellular SpaceFemaleHumansKidney DiseasesLupus Erythematosus, SystemicMembrane GlycoproteinsMiceMyeloid CellsNADPH Oxidase 2NADPH OxidasesNeutrophilsOrgan SizeCybb protein, mouseDNAMembrane GlycoproteinsNADPH Oxidase 2NADPH Oxidases

Identifiers

PMID23100627
PMCPMC3704198
OpenAlexW2110994039

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.